Table of Contents

Research Articles

• Research Articles | AuthorChoice

  Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

  Anna F. Farago, Beow Y. Yeap, Marcello Stanzione, Yin P. Hung, Rebecca S. Heist, J. Paul Marcoux, Jun Zhong, Deepa Rangachari, David A. Barbie, Sarah Phat, David T. Myers, Robert Morris, Marina Kem, Taronish D. Dubash, Elizabeth A. Kennedy, Subba R. Digumarthy, Lecia V. Sequist, Aaron N. Hata, Shyamala Maheswaran, Daniel A. Haber, Michael S. Lawrence, Alice T. Shaw, Mari Mino-Kenudson, Nicholas J. Dyson and Benjamin J. Drapkin

  Cancer Discov October 1 2019 9 (10) 1372-1387; DOI:10.1158/2159-8290.CD-19-0582

  
  

  A phase I/II clinical trial of the PARP inhibitor olaparib with the DNA-alkylating agent temozolomide in small-cell lung cancer provided preliminary evidence of efficacy, and a co-clinical trial using patient-derived xenografts revealed possible biomarkers for response.

• Research Articles | AuthorChoice

  Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

  Jeeyun Lee, Seung Tae Kim, Kyung Kim, Hyuk Lee, Iwanka Kozarewa, Peter G.S. Mortimer, Justin I. Odegaard, Elizabeth A. Harrington, Juyoung Lee, Taehyang Lee, Sung Yong Oh, Jung-Hun Kang, Jung Hoon Kim, Youjin Kim, Jun Ho Ji, Young Saing Kim, Kyoung Eun Lee, Jinchul Kim, Tae Sung Sohn, Ji Yeong An, Min-Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Jae J. Kim, Yang Won Min, Byung-Hoon Min, Nayoung K.D. Kim, Sally Luke, Young Hwa Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, AmirAli Talasaz, Simon J. Hollingsworth, Kyoung-Mee Kim and Won Ki Kang

  Cancer Discov October 1 2019 9 (10) 1388-1405; DOI:10.1158/2159-8290.CD-19-0442

  
  

  Biomarker-based treatment of patients with gastric cancer was associated with an improved overall response rate, and patients with MET amplifications who received savolitinib exhibited especially promising responses.

• Research Articles | AuthorChoice

  Epigenomics and Single-Cell Sequencing Define a Developmental Hierarchy in Langerhans Cell Histiocytosis

  Florian Halbritter, Matthias Farlik, Raphaela Schwentner, Gunhild Jug, Nikolaus Fortelny, Thomas Schnöller, Hanja Pisa, Linda C. Schuster, Andrea Reinprecht, Thomas Czech, Johannes Gojo, Wolfgang Holter, Milen Minkov, Wolfgang M. Bauer, Ingrid Simonitsch-Klupp, Christoph Bock and Caroline Hutter

  Cancer Discov October 1 2019 9 (10) 1406-1421; DOI:10.1158/2159-8290.CD-19-0138

  
  

  Single-cell analysis of Langerhans cell histiocytosis lesions revealed cellular and molecular heterogeneity suggestive of a developmental hierarchy shared among lesions.

• Research Articles

  The Mechanism of Anti–PD-L1 Antibody Efficacy against PD-L1–Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector

  Wenjuan Dong, Xiaojin Wu, Shoubao Ma, Yufeng Wang, Ansel P. Nalin, Zheng Zhu, Jianying Zhang, Don M. Benson, Kai He, Michael A. Caligiuri and Jianhua Yu

  Cancer Discov October 1 2019 9 (10) 1422-1437; DOI:10.1158/2159-8290.CD-18-1259

  
  

  The counterintuitive response of some PD-L1- tumors to anti–PD-L1 therapy may be a result of PD-L1 expression on natural killer (NK) cells, which can be triggered by contact between NK cells and myeloid leukemia cells.

• Research Articles

  A Mutation in Histone H2B Represents a New Class of Oncogenic Driver

  Richard L. Bennett, Aditya Bele, Eliza C. Small, Christine M. Will, Behnam Nabet, Jon A. Oyer, Xiaoxiao Huang, Rajarshi P. Ghosh, Adrian T. Grzybowski, Tao Yu, Qiao Zhang, Alberto Riva, Tanmay P. Lele, George C. Schatz, Neil L. Kelleher, Alexander J. Ruthenburg, Jan Liphardt and Jonathan D. Licht

  Cancer Discov October 1 2019 9 (10) 1438-1451; DOI:10.1158/2159-8290.CD-19-0393

  
  

  Mutations in the bodies of core histone proteins recur in cancers; the most common one (H2B^E76K) destabilizes nucleosomes, increases chromatin accessibility, alters gene expression, and increases proliferation of normal epithelial cells.

• Research Articles | AuthorChoice

  Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis

  Justin Taylor, Maria Sendino, Alexander N. Gorelick, Alessandro Pastore, Matthew T. Chang, Alexander V. Penson, Elena I. Gavrila, Connor Stewart, Ella M. Melnik, Florisela Herrejon Chavez, Lillian Bitner, Akihide Yoshimi, Stanley Chun-Wei Lee, Daichi Inoue, Bo Liu, Xiao J. Zhang, Anthony R. Mato, Ahmet Dogan, Michael G. Kharas, Yuhong Chen, Demin Wang, Rajesh K. Soni, Ronald C. Hendrickson, Gorka Prieto, Jose A. Rodriguez, Barry S. Taylor and Omar Abdel-Wahab

  Cancer Discov October 1 2019 9 (10) 1452-1467; DOI:10.1158/2159-8290.CD-19-0298

  
  

  Recurrent and lineage-specific mutations in the nuclear-export receptor XPO1 alter the distribution of proteins in the nucleus and cytoplasm and promote oncogenesis in vitro and in vivo.